587 related articles for article (PubMed ID: 15717010)
1. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults.
Lipton SA
NeuroRx; 2004 Jan; 1(1):101-10. PubMed ID: 15717010
[TBL] [Abstract][Full Text] [Related]
2. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
Lipton SA
J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S61-74. PubMed ID: 15665416
[TBL] [Abstract][Full Text] [Related]
3. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism.
Lipton SA
Curr Alzheimer Res; 2005 Apr; 2(2):155-65. PubMed ID: 15974913
[TBL] [Abstract][Full Text] [Related]
4. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation.
Lipton SA
Curr Drug Targets; 2007 May; 8(5):621-32. PubMed ID: 17504105
[TBL] [Abstract][Full Text] [Related]
5. Inflammatory mediators leading to protein misfolding and uncompetitive/fast off-rate drug therapy for neurodegenerative disorders.
Lipton SA; Gu Z; Nakamura T
Int Rev Neurobiol; 2007; 82():1-27. PubMed ID: 17678953
[TBL] [Abstract][Full Text] [Related]
6. The chemical biology of clinically tolerated NMDA receptor antagonists.
Chen HS; Lipton SA
J Neurochem; 2006 Jun; 97(6):1611-26. PubMed ID: 16805772
[TBL] [Abstract][Full Text] [Related]
7. Possible role for memantine in protecting retinal ganglion cells from glaucomatous damage.
Lipton SA
Surv Ophthalmol; 2003 Apr; 48 Suppl 1():S38-46. PubMed ID: 12852433
[TBL] [Abstract][Full Text] [Related]
8. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond.
Lipton SA
Nat Rev Drug Discov; 2006 Feb; 5(2):160-70. PubMed ID: 16424917
[TBL] [Abstract][Full Text] [Related]
9. Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma.
Seki M; Lipton SA
Prog Brain Res; 2008; 173():495-510. PubMed ID: 18929130
[TBL] [Abstract][Full Text] [Related]
10. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease.
Rogawski MA; Wenk GL
CNS Drug Rev; 2003; 9(3):275-308. PubMed ID: 14530799
[TBL] [Abstract][Full Text] [Related]
11. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
Sonkusare SK; Kaul CL; Ramarao P
Pharmacol Res; 2005 Jan; 51(1):1-17. PubMed ID: 15519530
[TBL] [Abstract][Full Text] [Related]
12. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy.
Kornhuber J; Weller M
Biol Psychiatry; 1997 Jan; 41(2):135-44. PubMed ID: 9018383
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of action of memantine.
Johnson JW; Kotermanski SE
Curr Opin Pharmacol; 2006 Feb; 6(1):61-7. PubMed ID: 16368266
[TBL] [Abstract][Full Text] [Related]
14. Alzheimer's disease and the glutamate NMDA receptor.
Doraiswamy PM
Psychopharmacol Bull; 2003; 37(2):41-9. PubMed ID: 14566213
[TBL] [Abstract][Full Text] [Related]
15. Management of moderate to severe Alzheimer's disease: focus on memantine.
Dominguez E; Chin TY; Chen CP; Wu TY
Taiwan J Obstet Gynecol; 2011 Dec; 50(4):415-23. PubMed ID: 22212311
[TBL] [Abstract][Full Text] [Related]
16. N-methyl-D-aspartate receptor channel blockers prevent pentylenetetrazole-induced convulsions and morphological changes in rat brain neurons.
Zaitsev AV; Kim KKh; Vasilev DS; Lukomskaya NY; Lavrentyeva VV; Tumanova NL; Zhuravin IA; Magazanik LG
J Neurosci Res; 2015 Mar; 93(3):454-65. PubMed ID: 25359451
[TBL] [Abstract][Full Text] [Related]
17. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity.
Chen HS; Pellegrini JW; Aggarwal SK; Lei SZ; Warach S; Jensen FE; Lipton SA
J Neurosci; 1992 Nov; 12(11):4427-36. PubMed ID: 1432103
[TBL] [Abstract][Full Text] [Related]
18. [Glutamate-related excitotoxicity neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer's disease and vascular dementia].
Tanović A; Alfaro V
Rev Neurol; 2006 May 16-31; 42(10):607-16. PubMed ID: 16703529
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotection against excitotoxicity by N-alkylglycines in rat hippocampal neurons.
Valera E; Fernández-Salguero PM; Planells-Cases R; Messeguer A; Van Den Nest W; Carreño C; Ferrer-Montiel A; Merino JM
Neuromolecular Med; 2002; 2(3):271-80. PubMed ID: 12622405
[TBL] [Abstract][Full Text] [Related]
20. [The clinical relevance of memantine use].
Sobów T
Psychiatr Pol; 2004; 38(2):321-30. PubMed ID: 15307296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
